BANTHINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BANTHINE (BANTHINE).
Anticholinergic; competitively blocks muscarinic acetylcholine receptors, inhibiting parasympathetic impulses.
| Metabolism | Hepatic metabolism (hydrolysis); active metabolite (methylscopolamine). |
| Excretion | BANTHINE (methantheline) is primarily eliminated via renal excretion (approximately 70% unchanged) with the remainder as metabolites. Biliary/fecal elimination accounts for less than 15%. Total recovery in urine and feces is nearly complete. |
| Half-life | Terminal elimination half-life is approximately 2.5–3 hours in adults with normal renal function. In elderly or those with renal impairment, half-life may be prolonged to 6–8 hours, requiring dose adjustment. |
| Protein binding | Approximately 50% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vd approximately 1.5–3.0 L/kg, indicating extensive tissue distribution. Large Vd due to lipophilicity and binding to muscarinic receptors. |
| Bioavailability | Oral bioavailability is low and erratic, ranging from 5% to 20% due to extensive first-pass metabolism. IM bioavailability is nearly 100%. |
| Onset of Action | Oral: 30–60 minutes. Parenteral (IM/IV): 5–10 minutes. |
| Duration of Action | Oral: 4–6 hours (variable based on dose and anticholinergic tolerance). Parenteral: 2–4 hours. Clinical anticholinergic effects (e.g., decreased secretions, tachycardia) may persist longer. |
| Molecular Weight | 420.31 |
Adults: 50 mg orally four times daily, before meals and at bedtime.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use caution in severe renal impairment (GFR <30 mL/min) due to potential accumulation. Reduce dose if anticholinergic side effects occur. |
| Liver impairment | No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to reduced clearance. |
| Pediatric use | Children: 0.5 mg/kg orally four times daily; maximum single dose 25 mg. |
| Geriatric use | Initiate at lower dose (e.g., 25 mg three times daily) and titrate slowly due to increased sensitivity to anticholinergic effects; monitor for confusion, constipation, and urinary retention. |
| 1st trimester | BANTHINE (methantheline bromide) is an anticholinergic agent. Limited human data; animal studies suggest risk. Avoid use during first trimester due to potential anticholinergic effects on fetal development. |
| 2nd trimester | Use only if clearly needed and potential benefit justifies risk to fetus. May cause maternal anticholinergic effects (tachycardia, ileus) that could affect pregnancy. |
| 3rd trimester | Avoid near term as anticholinergics may inhibit uterine contractions and cause neonatal anticholinergic effects (e.g., meconium ileus, respiratory depression). |
Clinical note
Comprehensive clinical and safety monograph for BANTHINE (BANTHINE).
| Placental transfer | Crosses placenta; degree not well-quantified in humans. Animal studies demonstrate placental transfer. |
| Breastfeeding | BANTHINE is excreted into breast milk in small amounts. Anticholinergic effects in infants (e.g., tachycardia, constipation, dry mouth) are possible. Avoid breastfeeding or use with caution; monitor infant for anticholinergic symptoms. |
■ FDA Black Box Warning
None.
| Serious Effects |
Glaucoma (narrow-angle)Obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy)Gastrointestinal obstruction (e.g., pyloric stenosis, paralytic ileus)Myasthenia gravis (use only under specialist supervision)Hypersensitivity to methantheline bromide or any component
| Precautions | May precipitate glaucoma, urinary retention, or tachycardia. Caution in GI obstruction, myasthenia gravis, and autonomic neuropathy. |
| Food/Dietary | Avoid alcohol and caffeine-containing beverages as they may increase gastric acid secretion and reduce drug efficacy. Take on an empty stomach for optimal absorption; food may delay absorption. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) – limited data; potential for adverse effects in infant. |
| Teratogenic Risk | Teratogenic effects not established in humans; animal studies insufficient. In first trimester, no structural anomalies consistently associated. Third trimester use may cause transient neonatal bradycardia or hypotonia due to anticholinergic effects. No documented risk of spontaneous abortion or preterm delivery. |
| Fetal Monitoring | Monitor maternal heart rate and blood pressure for anticholinergic effects (tachycardia, hypertension). Assess fetal heart rate pattern if maternal hypotension occurs. Monitor for signs of urinary retention or constipation in mother. No routine fetal monitoring mandated absent maternal compromise. |
| Fertility Effects | Anticholinergic effects may reduce vaginal lubrication. No direct impairment of ovulation or spermatogenesis documented. Theoretical risk of decreased sperm motility from impaired cholinergic transmission in seminal tract. Clinical significance unknown. |
| Clinical Pearls |
| BANTHINE (methantheline bromide) is an anticholinergic used primarily for peptic ulcer disease. Onset of action is 30-60 minutes orally; avoid in patients with glaucoma, myasthenia gravis, or obstructive uropathy. Monitor for anticholinergic side effects: dry mouth, blurred vision, constipation, urinary retention. Tachycardia may occur; use cautiously in elderly and patients with cardiac disease. Discontinue if paralytic ileus or severe allergic reaction occurs. |
| Patient Advice | Take BANTHINE 30 minutes before meals and at bedtime for best effect on ulcer pain. · Avoid driving or operating machinery if you experience blurred vision or dizziness. · Drink plenty of water to help prevent constipation. · Do not crush or chew tablets; swallow whole. · Report severe dry mouth, difficulty urinating, or eye pain immediately. |